Paolini John F. sold $8.9M of KNSA
Paolini John F. (CHIEF MEDICAL OFFICER) sold 96,000 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $93.09 ($92.02–$97.77, $8.94M total) across 10 trades over 2026-10-30 to 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction represents a material insider divestment for a micro‑cap biotech, likely prompting short‑term price softness.
Market read
Insider sales are closely watched; this filing may influence short‑term trading sentiment for KNSA.
What to watch
Potential upcoming clinical data releases that could offset sell‑off pressure.
Background
SEC Form 4 filing discloses a CMO’s open‑market sale of 96,000 KNSA shares under a pre‑arranged 10b5‑1 plan.
Ticker impact
Chief Medical Officer John Paolini sold $8.9M of KNSA shares via a 10b5‑1 plan, reducing his stake to 69,922 shares.
likely modest downward pressure as the market prices the insider sell.
A $9M sale by a C‑level insider is material for a micro‑cap biotech; however, the sale is pre‑arranged under a 10b5‑1 plan, limiting informational content.
Market effects
May raise caution among biotech investors monitoring insider activity.
Limited to U.S. biotech market.
Minimal.
Counterpoint
The sale could be purely liquidity‑driven and not reflect company fundamentals.
Key entities
- companyKiniksa Pharmaceuticals International plc
Biopharma listed on NASDAQ under ticker KNSA.
- personJohn F. Paolini
Chief Medical Officer of KNSA, insider seller.
